InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
5
T+90 hit rate
33%
T+90 mean return
-16.3%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Mehta Vimal, CEO, Président et secrétaire. Officer active across 1 company, notably BioXcel Therapeutics, Inc.. In total, 22 reports have been logged. Split: 0 buy · 5 sells. Total volume traded: €24.6m. Activity tracked since 25 June 2021. The latest transaction was disclosed on 20 May 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations22 total
219 sharesCommon StockSEC:0001104659-26-075298:0
49,758 sharesCommon StockSEC:0001104659-26-065836:0
19,419 shares@ US$1.0870.059% mcap0.1% of flowCommon StockSEC:0001104659-26-065836:1
163 sharesCommon StockSEC:0001104659-25-090518:0
219 sharesCommon StockSEC:0001104659-25-090518:1
15,625 sharesCommon StockSEC:0001104659-25-069703:0
162 sharesCommon StockSEC:0001104659-25-024531:0
2,610 sharesCommon StockSEC:0001104659-24-129462:0
2,609 sharesCommon StockSEC:0001104659-24-100751:0
2,609 sharesCommon StockSEC:0001104659-24-072999:0
609,221 sharesCommon StockSEC:0001104659-24-069195:0
2,610 sharesCommon StockSEC:0001104659-24-044861:0
2,609 sharesCommon StockSEC:0001104659-23-126924:0
2,610 sharesCommon StockSEC:0001104659-23-101635:0
2,609 sharesCommon StockSEC:0001104659-23-072396:0
6,500 shares@ US$25.79090.6% of flowCommon StockSEC:0001104659-23-064163:0
15,000 sharesCommon StockSEC:0001104659-23-061539:0
30,000 shares@ US$0.410.0% of flowCommon StockSEC:0001104659-23-035711:0
10,437 sharesCommon StockSEC:0001104659-23-033403:0
30,000 shares@ US$0.410.0% of flowCommon StockSEC:0001104659-22-128367:0
473,250 shares@ US$30.828349.6% of flowCommon StockSEC:0001104659-21-086948
473,250 shares@ US$30.828339.62% mcap50.0% of flowCommon StockSEC:0001104659-21-086948:0
22 of 22 declarations
About Mehta Vimal
Vimal Mehta is the CEO, President, and Secretary of BioXcel Therapeutics, Inc. He is responsible for the strategic and operational direction of the company, aiming to ensure its growth and profitability.
